Drug Database
Back to search

Poland· PL-100191043

Nalpain 10 mg/ml

A nalbuphine product containing nalbuphini hydrochloridum, registered in Poland by Orpha-Devel Handels und Vertriebs GmbH. The same ATC class is registered in 11 of our 19 countries.

ATC N02AF02

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedNalpain 10 mg/mlATCN02AF02REGISTER NO.PL-100191043PACKS LISTED2CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about nalbuphini hydrochloridumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Nalbuphine is registered in 11 of 19 countries.

Countries holding a registration under ATC N02AF02 (nalbuphine), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 7 of them publish a price we can compare per daily dose
Search nalbuphine products by name

Nalbuphine · ATC N02AF02

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Finlandprice
  • Franceprice
  • Germany
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Nalbuphini hydrochloridum
Manufacturer
Orpha-Devel Handels und Vertriebs GmbH
Country
Poland (PL)
ATC code
N02AF02
ATC class
Nalbuphine
Defined daily dose
80 mg, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    05909990639410
  • gtin
    04150011382261

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

148 interactions on record for nalbuphine.

Graded by severity as the source publishes them — 18 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check nalbuphine against other medicinesHow interaction checks work

Nalbuphine · interactions on record

148 records

  • 18 severe
  • 98 moderate
  • 32 info

Most severe, free to view

  • AlvimopanA06AH02severe
  • OpiumA07DA02severe
  • ChlorphenesinD01AE07severe
  • ChlorphenesinG01AX21severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Nalbuphine in 10 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All nalbuphine products

Authorised across Europe · EMA

The same active substance is authorised in 7 EEA countries. Names it is sold under:

  • Austria · Nalbuphin Amomed, Nubain
  • Czechia · Nalbuphin Orpha
  • Germany · Nalpain, Nubain
  • France · Nalbuphine Renaudin, Nalbuphine Serb
  • Greece · Nalpain
  • Hungary · Nalpain
  • Netherlands · Nalbufine Hcl Orpha

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/5862d341-2e0d-4845-b8df-6d9d5616ccc3
GET /v1/drugs/5862d341-2e0d-4845-b8df-6d9d5616ccc3?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Roztwór do wstrzykiwań",
  "source": "urpl",
  "strength": "10 mg/ml",
  "packaging": "05909990639410 ¦ Rpw ¦ 42652\n10 amp. 2 ml\n¦ UR/Z/4c/320/25 - 04150011382261",
  "substance": "Nalbuphini hydrochloridum 10 mg/ml",
  "common_name": "Nalbuphini hydrochloridum",
  "pl_product_id": "100191043",
  "pozwolenie_nr": "14424",
  "auth_procedure": "MRP",
  "authorisation_validity": "Bezterminowe"
}
API referenceMCP serverPlans

See everything about nalbuphine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console